{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "NSP",
  "name": "Insperity, Inc",
  "url": "https://orbyd.app/dossiers/NSP/",
  "json_url": "https://orbyd.app/dossiers/NSP.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Post-crash PEO turnaround: margin repair plus the Feb-2026 Workday HRScale launch drove a ~160% bounce off the $18.57 low, but worksite employees are still contracting (303k, -1% YoY) and the 2026-07-29 Q2 print is a hard binary. No accelerating narrative to chase yet — dormant for a momentum entry.",
  "invalidation_trigger": "A weekly close below $42 breaks the post-crash recovery base; a second worksite-employee guide cut on the 2026-07-29 print would confirm the core PEO engine is still contracting and end the turnaround thesis.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Earnings blackout: Q2 2026 print 2026-07-29 after close — binary risk, no fresh entries into the print.",
    "Core metric to watch is average paid worksite employees (WSEs): 303,049 in Q1 2026 (-1% YoY); FY guide 303k-307k implies continued decline.",
    "Auto-discovery theme tags ('cyclical-industrials', 'managed-care-health-services') are mislabels — NSP is a PEO/HR-services name whose health-cost pass-through is a margin risk, not a managed-care play.",
    "~5% dividend yield ($2.40 annualized) is a value-trap magnet; do not treat yield as downside protection on a shrinking-WSE turnaround.",
    "HRScale (Workday) went GA 2026-02-26; management frames $500M+ incremental revenue by 2028 — track disclosed client counts as the real turnaround tell."
  ],
  "body_markdown": "## Current Thesis\nInsperity is a professional employer organization (PEO) — it leases HR, payroll, and benefits administration to small and mid-sized US employers, and its single most important number is average paid worksite employees (WSEs). That number is shrinking: 303,049 in Q1 2026, down ~1% YoY (call 2026-05-01). The equity has already round-tripped violently — from a 52-week low of $18.57 to ~$48.35 (2026-07-24), a ~160% recovery — powered by a margin-repair story plus the 2026-02-26 general-availability launch of Insperity HRScale with Workday. That is a genuine narrative leg, but it is a turnaround off a washed-out base, not an accelerating momentum tape. WSEs still contract, GAAP profit is depressed, and the Q2 print on 2026-07-29 is a hard binary. For a momentum book this is dormant: the big mean-reversion move is behind it and the next leg is gated by an earnings gamble.\n\n## Bull Case\n- **Margin recovery is real and ahead of schedule.** Q1 2026 adjusted EBITDA was $103M and adjusted EPS $1.31, beating the $1.24 consensus (reported 2026-05-01). Management said gross-profit-per-WSE recovery outpaced its own scheduled cadence, which is why full-year adjusted-EBITDA guidance ($170–230M) held despite a shrinking employee base.\n- **Workday HRScale is the growth optionality.** The co-branded PEO-plus-Workday-HCM product hit general availability 2026-02-26. Early co-selling feedback cited clients willing to pay a 10–15% premium, and management has framed $500M+ of incremental revenue potential by 2028. If that converts, the WSE decline reverses and the multiple re-rates.\n- **Turnaround optics and a divided-but-improving Street.** Recent single-firm targets sit at $52 (Truist, maintained Hold, raised PT 2026-07-22) and $54 (Roth, May 2026), both above spot. The name recovered off deep-value levels ($18.57 low) as the 2025 benefits-cost blowup annualized out of the comps.\n- **~5% dividend** ($0.60/quarter, $2.40 annualized) pays the wait — though this cuts both ways (see traps below).\n\n## Bear Case\n- **The core engine is contracting.** Average paid WSEs fell ~1% YoY in Q1 2026 and printed at the low end of the forecast range. Full-year guidance of 303,000–307,000 implies a 1–2.3% decline. A PEO whose worksite headcount shrinks has no organic top-line engine; revenue growth (~2% YoY in Q1) is pricing, not volume.\n- **Reported earnings are hollow.** GAAP net income fell ~35% YoY to $33M in Q1 2026, and trailing-twelve-month net income is negative (~-$25M), so there is no meaningful P/E. The forward P/E near ~22 already prices a recovery that WSE trends have not yet delivered.\n- **Guidance has been the wound, not the salve.** The Q1 beat was overshadowed by soft guidance that sank the shares. The Q2 range (adjusted EPS $0.02–$0.50) is unusually wide — an admission of low forward visibility.\n- **Structural margin risk is health-cost inflation.** The 2025 blowup came from benefits/medical-cost pass-through. This is a health-cost-carrying business, so an insurance-inflation reacceleration re-opens the same wound.\n- **Consensus is Hold, and some aggregators peg the blended 12-month target below spot** even as individual banks sit at $52–54 — a split Street, not a conviction narrative.\n\n## Setup & Price Structure\n- Spot ~$48.35 (2026-07-24), market cap ~$1.85B. The 52-week range ($18.57–$61.65) frames the picture: recovered ~160% off the low, still ~22% under the prior 12-month high.\n- Price structure is a consolidation in the mid-to-high $40s, capped by the $52–54 analyst-target cluster and the $61 prior high. This is a base pressing against resistance, not a breakout above it.\n- There is no accelerating momentum signature — declining WSEs and soft reported earnings argue MATURING at best. The parabolic recovery leg off the bottom has already been paid out.\n- Beginner-trap flags to name plainly: the ~5% yield is a magnet for holding a weak name \"for the dividend\"; the print is ~2 trading days out, so a fresh entry here is a binary gamble; and buying a name whose core metric is still shrinking, into resistance, is chasing a recovery rather than catching a narrative.\n\n## Catalyst Calendar (next 30 days)\n\n- **Post-print quarterly dividend declaration** typically follows earnings (~$0.60/share, est.).\n\n## Elapsed catalysts\n\n- **2026-07-29 (Wed, after close): Q2 2026 earnings.** Consensus ~$0.33 adjusted EPS on ~$1.67B revenue. This is the binary — WSE trajectory, gross-profit-per-employee, and any hard HRScale booking/client numbers will set the tape. Earnings inside three trading days = avoid fresh entries into the print. *(passed 11d ago)*\n\n## What Would Change Our Mind\n- **Bull activation:** a worksite-employee inflection on 2026-07-29 — a full-year guide raised above 307,000 or a return toward YoY WSE growth — plus disclosed HRScale client counts. That would flip the turnaround toward accelerating and justify a fresh look on a clean breakout over the $52–54 shelf.\n- **Bear confirmation:** a second WSE guide cut or a margin miss on the print, or the price losing its recovery base.\n\n## Correlation Notes\n- NSP is cyclical to US small-business hiring — it tracks small-employer employment (NFIB hiring plans, ADP small-business payrolls) far more than the S&P tech complex.\n- PEO/payroll peer read-across: TriNet (TNET), Barrett Business Services (BBSI), Paychex (PAYX), ADP (ADP). Health-insurer medical-cost-trend commentary is a leading tell for NSP's benefits-margin risk.\n- The Workday (WDAY) relationship ties a slice of the equity story to Workday's SMB push; WDAY partnership commentary is a secondary read on HRScale traction.",
  "first_seen": "2026-07-20",
  "last_analyzed": "2026-07-26T08:09:47+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}